Patents by Inventor Guillaume Lessene

Guillaume Lessene has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination of a MCL-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
    Patent number: 10765680
    Abstract: A combination comprising a MCL-1 inhibitor and a taxane compound, and compositions and uses thereof.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: September 8, 2020
    Assignees: LES LABORATORIES SERVIER, NOVARTIS AG
    Inventors: Dale Porter, Ensar Halilovic, Maïa Chanrion, Ana Leticia Maragno, Olivier Geneste, Delphine Merino, James Whittle, François Vaillant, Jane Visvader, Geoffrey Lindeman, Guillaume Lessene, Elisabetta Marangoni
  • COMBINATION OF A MCL-1 INHIBITOR AND A TAXANE COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20190336505
    Abstract: A combination comprising a MCL-1 inhibitor and a taxane compound, and compositions and uses thereof.
    Type: Application
    Filed: January 5, 2018
    Publication date: November 7, 2019
    Inventors: Dale PORTER, Ensar HALILOVIC, Maïa CHANRION, Ana Leticia MARAGNO, Olivier GENESTE, Delphine MERINO, James WHITTLE, François VAILLANT, Jane VISVADER, Geoffrey LINDEMAN, Guillaume LESSENE, Elisabetta MARANGONI
  • Novel Anti-Cancer Agents
    Publication number: 20160145243
    Abstract: The present invention provides a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment of cancer in a subject comprising administering to said subject an effective amount of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is the use of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof in the preparation of a medicament for the treatment of cancer. In addition, the present invention also provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof.
    Type: Application
    Filed: November 19, 2015
    Publication date: May 26, 2016
    Inventors: Antony Wilks Burgess, Francesca Walker, Keith Geoffrey Watson, Helen Witchard, Guillaume Lessene
  • Anti-cancer agents
    Patent number: 9221799
    Abstract: The present invention provides a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment of cancer in a subject comprising administering to said subject an effective amount of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is the use of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof in the preparation of a medicament for the treatment of cancer. In addition, the present invention also provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: December 29, 2015
    Assignee: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Antony Wilks Burgess, Francesca Walker, Keith Geoffrey Watson, Helen Witchard, Guillaume Lessene
  • Novel Anti-Cancer Agents
    Publication number: 20150045365
    Abstract: The present invention provides a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is a method of treatment of cancer in a subject comprising administering to said subject an effective amount of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is the use of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof in the preparation of a medicament for the treatment of cancer. In addition, the present invention also provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof.
    Type: Application
    Filed: August 6, 2014
    Publication date: February 12, 2015
    Inventors: Antony Wilks Burgess, Francesca Walker, Keith Geoffrey Watson, Helen Witchard, Guillaume Lessene
  • Novel Anti-Cancer Agents
    Publication number: 20130261119
    Abstract: The present invention provides a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or pro-drug thereof. Further provided is a method of treatment of cancer in a subject comprising administering to said subject an effective amount of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof. Further provided is the use of a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof in the preparation of a medicament for the treatment of cancer. In addition, the present invention also provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutical acceptable derivative, salt or prodrug thereof.
    Type: Application
    Filed: October 27, 2011
    Publication date: October 3, 2013
    Applicant: The Walter and Eliza Hall Institute of Medical Research
    Inventors: Antony Wilks Burgess, Francesca Walker, Keith Geoffrey Watson, Helen Witchard, Guillaume Lessene